Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for zilganersen, an ...
Ionis Pharmaceuticals is dramatically lowering the price of its blockbuster hopeful Tryngolza (olezarsen) as it prepares to ...
Add Yahoo as a preferred source to see more of our stories on Google. This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma ...
12don MSN
Ionis Pharmaceuticals repriced drug ahead of key FDA decision, signals push into larger market
On Wednesday, Ionis Pharmaceuticals Inc. IONS said it is cutting the annual list price of its triglyceride-lowering drug Tryngolza (olezarsen) to $40,000 from $595,000. The move positions the therapy ...
Zacks.com on MSN
FDA Grants Priority Tag to Ionis' NDA for Alexander Disease Drug
Ionis Pharmaceuticals IONS announced that the FDA has granted priority review to its new drug application (NDA) seeking ...
Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Ionis Pharmaceuticals won approval from the Food and Drug Administration on ...
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on Tuesday released topline results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG). sHTG is a condition ...
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Ionis Pharmaceuticals' drug to prevent instances of severe swelling in various parts of the body of patients with a rare genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results